Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause

Cancer

Volumn 83, Issue 4, 1998, Pages 698-705

  Pujol, Pascal ^a   Daures, Jean Pierre ^b   Thezenas, Simon ^c   Guilleux, Fançoise ^c   Rouanet, Phillipe ^c   Grenier, Jean ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Dept de Biostatistiques   (France)

^c Lab d'Oncopharmacologie pharmacie Ctr Regl Lutte contre le Cancer V   (France)

Author keywords

Breast cancer; Estrogen receptors; Menopause; Menstrual cycle; Progesterone receptors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; DATA ANALYSIS; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HORMONE DEPENDENCE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MENOPAUSE; MENSTRUAL CYCLE; PROGESTERONE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0031813257     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<698::AID-CNCR10>3.0.CO;2-N     Document Type: Article

References (38)

1. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:2428-33.
2. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;36:2884-8.
3. Clark GM, McGuire WL. Steroid receptors and others prognostic factors in primary breast cancer. Semin Oncol 1988; 15:20-5.
4. Veronesi U, Luini A, Mariani L, DelVecchio M, Alvez D, Andreoli C, et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994;343:1544-6.
5. Senie RT, Rosen PP, Rhodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences the duration of disease-free survival. Ann Int Med 1991;115:337-42.
6. Fentiman IS, Gregory WM, Richards MA. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 344:402.
7. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996;73:1552-5.
8. Oliver DJ, Ingram DM. Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 1995;3:325-8.
9. Holdaway IM, Mason BH, Lethaby AE, Harman JE, France JT, Knox BS. Characteristics of the menstrual cycle at the time of surgery for breast cancer. Br J Cancer 1997;75: 413-6.
10. Badwe RA, Bettelheim R, Millis RR, Gregory W, Richards MA, Fentiman IS. Cyclical tumour variations in premenopausal women with early breast cancer. Eur J Cancer 1995;13: 2181-4.
11. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS Jr. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metabol 1988;67:334-40.
12. Silva JS, Georgiade GS, Dilley WG, McCarty KS, Wells SA, McCarty KS. Menstrual cycle-dependent variations of breast cyst fluid protein and sex steroid receptors in the normal human breast. Cancer 1983;51:1297-302.
13. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
14. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, et al. Oral contraceptive (OCP) use in increases proliferation and decrease oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48:206-10.
15. Markopoulos C, Berger U, Wilson P, Gazet JC, Coombes RC. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. BMJ 1988;296:1349-52.
16. Heise E, Görlich M. Estradiol receptor in human breast cancer throughout the menstrual cycle. Oncology 1982;39: 340-4.
17. Saez S, Martin PM, Chouvet CD. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res 1978;38:3468-73.
18. Coradini D, Cappelleti V, Miodini P, Ronchi E, Scavone G, Di fronzo G. Variations in estrogen and progesterone receptor content in premenopausal breast cancer patients throughout the menstrual cycle. Tumori 1984;70:339-44.
19. Weimer DA, Donegan WL. Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle. Breast Cancer Res Treat 1987; 10:273-8.
20. Axelrod DM, Menendez-Botet CJ, Kinne DW, Osborne M. Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menses. Cancer Invest 1988;6:1-14.
21. Holli K, Isola J, Hakama M. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient - fact or fallacy? Br J Cancer 1995;71:124-7.
22. Korenman SG. Comparative binding of estrogens and its relation to estrogenic potency. Steroids 1969;13:163-78.
23. Lowry OH, Roseborough N, Farr L, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193:265-75.
24. Romain S, Lainé Bidron C, Martin PM, Magdelenat H on behalf of the EORTC Receptor Study Group. Steroid receptor distribution in 47 892 Breast cancers. A collaborative study of 7 European laboratories. Eur J Cancer 1995;31:411-7.
25. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994;74:1601-6.
26. Thorpe SM. Immunological quantitation of nuclear receptors in human breast cancer. Relation to cytosolic estrogen and progesterone receptors. Cancer Res 1987;47: 1830-5.
27. Helin H, Isola J, Helle M, Koivula T. Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Br J Cancer 1990;62: 109-12.
28. Fernö M, Borg A, Sellberg G. Enzyme immunoassay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 1986;25: 171-5.
29. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321-30.
30. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term culture. Cancer Res 1976;36:4595-601.
31. Barrett-Lee PJ, Travers MT, McClelland RA, Lugmani Y, Coombes RC. Characterization of oestrogen receptor messenger RNA in human breast cancer. Cancer Res 1987;47: 6653-9.
32. Maudelonde T, Lavaud P, Salazar G, Laffargue F, Rochefort H. Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Breast Cancer Res Treat 1991;19:95-102.
33. Thorpe SM. Estrogen and progesterone receptor determination in breast cancer. Technology, biology and clinical significance. Acta Oncol 1988;27:1-19.
34. Fernö M, Borg A, Johansson U, Norgen A, Olsson H, Ryden S, et al. Estrogen and progesterone receptor analyses in more than 4000 human breast canecr samples. Acta Oncol 1990;29:129-35.
35. EORTC Breast Cancer Co-Operative Group. Revision of standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC workshop, held on March 16-17, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
36. Di Fronzo G, Coradini D, Cappelletti V, Miodini P, Granata G, Schwartz M, et al. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Anticancer Res 1990;10:1699-706.
37. McCarty KS Jr, Miller L, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109: 716-21.
38. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 1990;125:107-13.